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The major mechanism of imatinib (IM) resistance of CML is the reactivation of
ABL kinase either through BCR-ABL gene amplification or mutation. We investi-
gated the cytotoxicity of a pan-ABL tyrosine kinase inhibitor, ponatinib, and a
pan-histone deacetylase inhibitor, panobinostat, against IM-resistant CML cells
in vitro. Two different IM-resistant cell lines, K562/IM-R1 and Ba/F3/T315I were
evaluated in comparison with their respective, parental cell lines, K562 and Ba/
F3. K562/IM-R1 overexpressed BCR-ABL due to gene amplification. Ba/F3/T315I
was transfected with a BCR-ABL gene encoding T315I-mutated BCR-ABL. Pona-
tinib inhibited the growth of both K562/IM-R1 and Ba/F3/T315I as potently as it
inhibited their parental cells with an IC50 of 2–30 nM. Panobinostat also similarly
inhibited the growth of all of the cell lines with an IC50 of 40–51 nM. This was
accompanied by reduced histone deacetylase activity, induced histone H3 acetyla-
tion, and an increased protein level of heat shock protein 70, which suggested
disruption of heat shock protein 90 chaperone function for BCR-ABL and its
degradation. Importantly, the combination of ponatinib with panobinostat
showed synergistic growth inhibition and induced a higher level of apoptosis
than the sum of the apoptosis induced by each agent alone in all of the cell lines.
Ponatinib inhibited phosphorylation not only of BCR-ABL but also of downstream
signal transducer and activator of transcription 5, protein kinase B, and ERK1/2 in
both K562/IM-R1 and Ba/F3/T315I, and the addition of panobinostat to ponatinib
further inhibited these phosphorylations. In conclusion, panobinostat enhanced
the cytotoxicity of ponatinib towards IM-resistant CML cells including those with
T315I-mutated BCR-ABL.
C hronic myelogenous leukemia is a malignant transforma-tion of hematopoietic stem cells. The clinical stages of
CML consist of three different phases: a chronic phase that is
characterized by excessive proliferation, but retains the capac-
ity for differentiation; an accelerated phase that shows a rapid
progression after 4–6 years of the chronic phase; and a blast
crisis that results in a fatal acute leukemia.(1) The genetic
abnormality of CML is a reciprocal t(9,22)(q34;q11) chromo-
somal translocation, the so-called Philadelphia chromosome.
This abnormality generates a BCR-ABL fusion gene, resulting
in the expression of a leukemia-specific oncoprotein, BCR-
ABL, which is a potent tyrosine kinase that plays a central role
in CML pathogenesis.(2–5)
Current first-line treatment options for CML include the TKI
IM, and the second-generation agents, nilotinib and dasatinib.
These TKIs all inhibit the BCR-ABL tyrosine kinase and have
dramatically improved the prognosis of CML patients.(6–9) Nev-
ertheless, a small percentage of CML patients are primarily
refractory or secondarily resistant to these TKIs.(10,11) More-
over, the prognosis of patients in blast crisis is still poor despite
the use of these agents because of drug resistance. The major
mechanism of drug resistance of CML is reactivation of the
ABL kinase either through BCR-ABL gene mutation or through
gene amplification. Approximately 40% and 20% of the
observed drug resistance is due to BCR-ABL gene mutation and
gene amplification, respectively.(12,13) Therefore, new agents
that can overcome the reactivation of ABL kinase are needed.
Histone deacetylase inhibitors are emerging anticancer thera-
peutics. Histone deacetylase inhibitors promote the acetylation
of histones in treated cells, which results in chromatin in an
opened and transcriptionally permissive state, leading to apop-
tosis or the inhibition of proliferation. Recently, a pan-HDAC
inhibitor, panobinostat (formerly LBH589), has been reported
to have promising anticancer activity.(14) Panobinostat is a
hydroxamate analog and clinical studies of this agent are cur-
rently underway for various hematological malignancies
including Hodgkin’s lymphoma, cutaneous T-cell lymphoma,
AML, myelodysplastic syndrome, and multiple myeloma.(14,15)
Histone deacetylase inhibitors also induce the acetylation of
non-histone proteins such as HSP90, thereby inhibiting its
chaperone function. If panobinostat has such a function, then
panobinostat may suppress the association between HSP90 and
its client protein, BCR-ABL, leading to BCR-ABL polyubiqui-
tination and proteasomal degradation.(13,14,16) Thus, HDAC
inhibitors may overcome the cellular resistance of CML cells
to TKIs.
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The T315I mutation arises in the BCR-ABL kinase domain
from the beginning or during treatment with TKIs including
IM, nilotinib, and dasatinib and this mutation has been identi-
fied in up to 20% of patients with TKI-resistant CML.(13,17)
This mutation confers CML resistance not only to IM but also
to the second-generation TKIs such as nilotinib and dasa-
tinib.(18,19) The T315I residue is located in the gatekeeper
region of the ATP-binding site of BCR-ABL, resulting in
structural inhibition of the binding of IM, nilotinib, and dasa-
tinib to this region.(19,20) A new pan-ABL tyrosine kinase inhi-
bitor, ponatinib, is structurally designed to accommodate
T315I mutation through its carbon–carbon triple bond link-
age.(19) Ponatinib has been investigated in a phase II PACE
clinical trial in patients who had CML or Philadelphia chromo-
some-positive acute lymphoblastic leukemia with resistance or
intolerance to nilotinib or dasatinib or with BCR-ABL T315I
mutation. By 12 months of treatment, 56% of 267 patients
with chronic phase CML had achieved a major cytogenetic
response.(17) Thus, ponatinib is a promising therapeutic option
in patients with all kinds of BCR-ABL mutation, including
T315I.
We hypothesized that the combination of panobinostat and
ponatinib may overcome drug resistance and result in high
therapeutic efficacy in CML through the combination of the
different mechanisms of action of each agent. To test this
hypothesis, the K562/IM-R1 cell line and the Ba/F3/T315I cell
line were used to evaluate the cytotoxicity of panobinostat and
ponatinib. The K562/IM-R1 cell line that was established in
our previous study overexpresses BCR-ABL due to BCR-ABL
gene amplification.(21) The Ba/F3/T315I cell line is transfected
with a BCR-ABL gene encoding T315I-mutated BCR-ABL.(22)
Materials and Methods
Cell lines and reagents. Imatinib mesylate and panobinostat
were kindly supplied by Novartis-Pharma (Basel, Switzerland).
Ponatinib was purchased from ARIAD Pharmaceuticals (Cam-
bridge, MA, USA). Imatinib mesylate was dissolved in sterile
water; panobinostat and ponatinib were dissolved in DMSO.
The human CML cell line K562 and its IM-resistant variant
K562/IM-R1, and the BCR-ABL-transfected cell line Ba/F3
and its IM-resistant variant Ba/F3/T315I, were cultured in
RPMI-1640 media with 10% FBS and maintained in a 5%
CO2-humidified atmosphere at 37°C.
Proliferation assay. To evaluate the proliferative activity of
each cell line, the XTT assay was carried out according to the
manufacturer’s instructions (Roche, Indianapolis, IN, USA)
with slight modifications.(21) Briefly, 1 mL cells (5 9 104/mL)
was incubated for 24 h in a 24-well plate, followed by the
addition of a 10-lL aliquot of different concentrations of IM,
panobinostat, or ponatinib, alone or in combination. The cells
were incubated for a further 72 h, and then a 100-lL aliquot
was transferred to a 96-well microplate. The cells were mixed
with 50 lL XTT and incubated for another 4 h at 37°C.
Absorbance at 480 nm was analyzed using spectrophotometry
with a fluorescent microplate reader (SpectraMax 250; Molecu-
lar Device Japan, Ashiya, Japan). The IC50 values were calcu-
lated from the growth inhibition curves generated for each
treatment.
Calculation of CI. Combination index analysis provides quan-
titative information on drug interactions. The CI method was
based on that described by Chou and Talalay,(23) and the val-
ues were determined by using the IC50 values of their cell
lines and the computer software CalcuSyn (version 2.0)
(Biosoft, Great Shelford, UK). Combination index values less
than, equal to, and more than 1 indicate synergism, additivity,
and antagonism, respectively.
Quantitation of apoptotic cell death. To evaluate cytotoxicity,
apoptotic cell death was determined as phosphatidylserine
externalization by using the annexin V–FLUOS Staining kit
(Roche). At 48 h after treatment, the cells were collected by
centrifugation (253 g for 5 min) and washed in PBS and cen-
trifuged again. The pellets were resuspended in 50 lL FITC-
conjugated annexin V mixed with 50 lL propidium iodide.
Samples were added to 500 lL HEPES buffer and analyzed
by FACS analysis using FACSCanto II (BD Bioscience, Frank-
lin Lakes, NJ, USA). Annexin V-positive cells were considered
to be apoptotic.
Western blot analysis. Protein lysates were extracted from
the cells (1 9 107 cells) after treatment for 24 h using the
Qproteome Mammalian Protein Prep Kit (Qiagen, Hilden, Ger-
many). The lysates were applied to 7.5% or 12% Mini-PRO-
TEAN TGX Precast Gels (Bio-Rad, Hercules, CA, USA) and
were electrophoresed and transferred onto Immobilon-P mem-
branes (Millipore, Billerica, MA, USA). The membranes were
probed using standard techniques with the primary antibodies,
and subsequently with the secondary antibodies. Amersham
ECL Prime Western Blotting Detection Reagent and Image-
Quant LAS4000mini (GE Healthcare Life Sciences, Little
Chalfont, UK) were used to visualize and quantify protein
signals.
Rabbit polyclonal anti-BCR, anti-phospho-BCR (Tyr177),
anti-AKT, anti-phospho AKT (Ser473), anti-ERK1/2, anti-
phospho-ERK1/2, anti-histone H3 and anti-HSP70, rabbit mon-
oclonal anti-phospho-STAT5 (Tyr694) (all from Cell Signaling
Technology, Beverly, MA, USA), mouse monoclonal anti-
STAT5 (Santa Cruz Biotechnology, Dallas, TX, USA), rabbit
polyclonal anti-acetylated histone H3 (Millipore), mouse mon-
oclonal anti-HSP90 (Enzo Life Science, Farmingdale, NY,
USA), and anti-actin (Sigma, St. Louis, MO, USA) antibodies
were used as the primary antibodies. Blocking One and Block-
ing One-P (Nacalai Tesque, Kyoto, Japan) were used for the
antibody dilutions. Anti-rabbit IgG–HRP-linked antibody (Cell
Signaling Technology) and anti-mouse IgG–HRP -linked anti-
body (GE Healthcare Life Sciences) were used as the sec-
ondary antibodies.
Activity of HDAC. Activity of HDAC was determined using
an HDAC assay kit (Active Motif, Carlsbad, CA, USA).
Briefly, 30 lL nuclear extracts, which were extracted from cell
samples treated for 12 h with the Qproteome Nuclear Protein
kit (Qiagen), were incubated with 1 mM HDAC substrate in
the assay buffer in a total volume of 50 lL for 1 h at 37°C,
followed by termination of the reaction by addition of 50 lL
HDAC developing solution. The fluorescence intensity was
measured at a wavelength of 405 nm.
Statistical analyses. All statistical analyses were carried out
using Microsoft Excel 2007 software (Microsoft, Redmond,
WA, USA). All graphs were generated using GraphPad Prism
software (version 5.0) (GraphPad Software, San Diego, CA,
USA). Values of P < 0.05 were considered statistically signifi-
cant.
Results
Synergistic cytotoxicity of panobinostat and ponatinib towards
CML cell lines. Growth inhibitory effects of IM, or of panobi-
nostat or ponatinib alone or in combination, on K562 cells,
K562/IM-R1 cells, Ba/F3 cells, and Ba/F3/T315I cells were
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | July 2016 | vol. 107 | no. 7 | 1030
Original Article
Panobinostat and ponatnib against imatinib-resistant CML www.wileyonlinelibrary.com/journal/cas
determined using the XTT assay (Tables 1,2 and Figs 1,2).
This assay indicated that K562/IM-R1 cells and Ba/F3/T315I
cells were 12-fold and 13-fold more IM-resistant, respectively,
than their parental counterpart (Table 1, Fig. 1). In contrast,
panobinostat equally inhibited the growth of K562 cells, K562/
IM-R1 cells, Ba/F3 cells, and Ba/F3/T315I cells with IC50 val-
ues of between 40–51 nM (Table 2, Fig. 2). Ponatinib also
inhibited the growth of both IM-resistant K562/IM-R1 cells
and Ba/F3/T315I cells as potently as it inhibited the growth of
their respective parental K562 and Ba/F3 cells (Table 2,
Fig. 2). Importantly, the combination of panobinostat and
ponatinib showed enhanced growth inhibitory effects on all of
the cell lines compared to either agent alone (Table 2, Fig. 2).
The CI that was calculated based on their IC50 values clearly
showed the synergy between these agents in all of the cell
lines (Fig. 3).
We further evaluated drug-induced apoptosis of these cells
using flow cytometry. When the cells were treated for 48 h
with panobinostat or ponatinib either alone or in combination,
the combination of the two agents induced greater apoptotic
cell death than the sum of apoptotic cell death induced by each
agent alone in all of the cell lines (Table 3, Fig. 4a–d). More-
over, 30 nM ponatinib combined with 30 nM panobinostat
was as cytotoxic as 50 nM ponatinib alone against Ba/F3/
T315I cells (Fig. 4e).
Thus, panobinostat and ponatinib showed synergistic cyto-
toxicity towards IM-resistant cell lines, whose resistance was
caused by either BCR-ABL gene amplification or by BCR-ABL
T315I mutation. The cytotoxicity was as potent as that shown
towards IM-sensitive cell lines.
Inhibition of BCR-ABL autophosphorylation in CML cell lines by
panobinostat and/or ponatinib. The protein expression levels of
BCR-ABL and autophosphorylated BCR-ABL were deter-
mined by Western blotting of cell lines after treatment with
panobinostat or ponatinib, alone or in combination. The consti-
tutive expression level of BCR-ABL was higher in K562/IM-
R1 cells than in K562 cells, indicating the overexpression of
the ABL kinase by BCR-ABL gene amplification in this cell
line (Fig. 5a). This result was consistent with our previous
findings.(21)
Treatment with ponatinib inhibited the autophosphorylation
of BCR-ABL in all cell lines, indicating inhibition of ABL
kinase activity. The expression level of BCR-ABL was
unchanged by this treatment. Treatment with panobinostat
reduced the protein expression of BCR-ABL in all cell lines,
suggesting that it induced degradation of the BCR-ABL pro-
tein (Fig. 5b–e). The detected autophosphorylation of BCR-
ABL was also reduced by panobinostat, which reflected the
decreased expression of the BCR-ABL protein in the presence
of panobinostat. This degradation of BCR-ABL might be attri-
butable to the disruption of the chaperone function of HSP90
by panobinostat. It was noted that the combination of ponatinib
with panobinostat augmented the inhibition of BCR-ABL
autophosphorylation in all of the cell lines (Fig. 5b–e).
Inhibition of BCR-ABL downstream signal pathways in CML cell
lines by panobinostat and/or ponatinib. BCR-ABL-dependent
signal transduction is critical to the vigorous proliferation of
CML cells. Signal transducer and activator of transcription 5,
AKT, and ERK1/2 are signaling molecules that are located
downstream in BCR-ABL signal pathways.(12) Ponatinib inhib-
ited the phosphorylation of STAT5, AKT, and ERK1/2 in all
of the cell lines including in the cell line with T315I mutated
BCR-ABL (Fig. 5b–e). Panobinostat also reduced the phospho-
rylation of these downstream signals in all of the cell lines in
a concentration-dependent manner (Fig. 5b–e). Moreover, the
phosphorylation of downstream signals was more potently
Table 1. Sensitivity of CML cell lines to imatinib
IC50 (lM)
K562 K562/IM-R1 Ba/F3 Ba/F3/T315I
Imatinib 0.6 7.6 (12.6) 0.6 7.8 (13.0)
Cells were incubated with imatinib for 72 h, followed by XTT assay.
IC50 values, which indicate the 50% growth inhibitory concentration,
are shown. Numbers in parentheses indicate fold resistance relative to
parental cells.
Table 2. Sensitivity of CML cell lines to panobinostat and/or
ponatinib
IC50 (lM)
K562 K562/IM-R1 Ba/F3 Ba/F3/T315I HL60
Panobinostat 50.0 51.0 40.0 47.0 29.9
Ponatinib 2.0 3.8 5.0 30.0 796
Combination 0.7 1.3 3.7 10.0 32.1
Cells were incubated with the same concentration of panobinostat,
ponatinib, or their combination for 72 h, followed by XTT assay. IC50
values, which indicate the 50% growth inhibitory concentration, are
shown. HL60 cells that do not express the BCR-ABL protein were used
as a negative control.
Fig. 1. Cellular sensitivity to imatinib mesylate
(IM). The CML cell lines and their respective IM-
resistant variants, K562 and K562/IM-R1 cells (a), Ba/
F3 and Ba/F3/T315I cells (b) were incubated for 72 h
with IM at various concentrations, followed by the
XTT assay for evaluation of cell proliferation.
Proliferation was evaluated as a percentage of that
in cells not treated with IM. The dotted line
indicates 50% proliferation that was used to
calculate the IC50 values.
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inhibited by the combination of ponatinib and panobinostat
than by each single agent (Fig. 5b–e). The strong inhibition of
phosphorylation of STAT5 in K562 and Ba/F3 cells, of AKT
in K562/IM-R1 and Ba/F3 cells, and of ERK1/2 in K562 and
K562/IM-R1 cells by 5 nM ponatinib alone, may have masked
any additional effect of panobinostat. Interestingly, the expres-
sion of the AKT protein was reduced by panobinostat, suggest-
ing the possibility that AKT is a client protein of HSP90.
Thus, the inhibition of ABL-kinase activity by ponatinib
combined with the induced degradation of BCR-ABL by
panobinostat resulted in a synergistic decrease in the phospho-
rylation of BCR-ABL and its downstream signaling pathways.
Inhibition of HDAC activity, induction of histone H3 acetyla-
tion, and augmentation of HSP70 protein expression in CML cell
lines by panobinostat or panobinostat plus ponatinib. The major
mechanism of action of panobinostat is inhibition of HDAC
activity. The activity of HDAC was therefore measured in all
of the cells after treatment with panobinostat or with panobi-
nostat plus ponatinib. The activity of HDAC was significantly
inhibited by panobinostat regardless of the presence of pona-
tinib in all of the cell lines (Fig. 6). Activity of HDAC was
unchanged in these cell lines after treatment with IM or pona-
tinib alone (data not shown).
Western blot analysis showed the acetylation of histone H3
in cells after treatment that included panobinostat (Fig. 7a).
The level of the non-histone protein, HSP90 was unchanged
Fig. 2. Cellular sensitivity to panobinostat and/or
ponatinib. The CML cell lines and their respective
imatinib mesylate (IM)-resistant variants, K562 cells
(a) K562/IM-R1 cells (b), Ba/F3 cells (c), and Ba/F3/
T315I cells (d) were incubated with ponatinib or
panobinostat, alone or in combination, for 72 h at
the indicated concentrations within the range of
0.1–100 nM, followed by XTT assays for evaluation
of cell proliferation. Proliferation was evaluated as
a percentage of that in cells not treated with
ponatinib and/or panobinostat. The dotted line
indicates 50% proliferation that was used to
calculate the IC50 values.
Fig. 3. Combination index (CI) values evaluated for panobinostat
and ponatinib. The CI values evaluated for panobinostat and pona-
tinib for the indicated cell lines were calculated using the computer
software CalcuSyn (version 2.0). CI < 1, synergistic effect; Cl = 1, addic-
tive effect; CI > 1, antagonistic effect.
Table 3. Induction of apoptosis in CML cell lines by panobinostat
and/or ponatinib
Mean values (%)
K562 K562/IM-R1 Ba/F3 Ba/F3/T315I
Panobinostat 20.4 17.8 5.4 12.4
Ponatinib 34.1 23.3 24.7 36.7
Combination 70.3 65.4 44.9 71.9
Cells were incubated with panobinostat, ponatinib, or their combina-
tion at a concentration of 10 nM (K562 cells, K562/IM-R1 cells, Ba/F3
cells) or 30 nM (Ba/F3/T315I cells) per agent for 48 h, followed by flow
cytometric analysis of apoptosis. Apoptotic cell death was evaluated
by annexin V positivity. Mean values are shown.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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by treatment of K562 cells with panobinostat or with panobi-
nostat plus ponatinib. Nevertheless, panobinostat increased the
protein level of HSP70 in K562 cells (Fig. 7b), which is sug-
gestive of inhibition of the chaperone function of HSP90.(24)
Discussion
Imatinib resistance in CML is attributed to a variety of mecha-
nisms including reactivation of the BCR-ABL kinase,
increased efflux of the drug through P-glycoprotein, and com-
pensation for the loss of BCR-ABL signaling by other kinase
pathways such as Src-family kinases.(12,25–32) Therefore, to
overcome IM resistance the use of new agents with anti-CML
activity that is mediated through different mechanisms of
action is necessary. As the major reason for IM resistance is
reactivation of the BCR-ABL kinase, we investigated the cyto-
toxic effects of the new BCR-ABL TKI ponatinib combined
with the HDAC inhibitor panobinostat against IM-resistant cell
lines, including a cell line that expresses a BCR-ABL kinase
that is active due to T315I mutation.
The present study clearly shows that both ponatinib and
panobinostat showed antiproliferative effects and cytotoxicity
against the IM-resistant variant K562/IM-R1 cells with BCR-
ABL amplification and Ba/F3/T315I cells with BCR-ABL with
a T315I kinase mutation (Figs 2–4d). Moreover, the combina-
tion of panobinostat and ponatinib showed synergistic antiprolif-
erative and cytotoxic effects on these cell lines (Fig. 3). Thus,
ponatinib inhibited the constitutive ABL kinase activity in cells
expressing gene-amplified active ABL or in cells expressing
ABL with a T315I mutation (Fig. 5b–e). This inhibition of ABL
kinase activity was accompanied by inhibition of the phosphory-
lation of downstream signaling molecules. Panobinostat inhib-
ited HDAC activity, resulting in acetylated histone H3, which
might result in inhibition of the proliferation of CML cells.(14)
Moreover, HSP70 expression was augmented by panobinostat,
suggesting that the chaperone function of HSP90 for BCR-ABL
was disrupted (Fig. 7b).(24,33) Therefore, synergistic cytotoxicity
exerted by the combination of panobinostat and ponatinib was
attributed to their different mechanisms of action: inhibition of
the ABL kinase and inhibition of HDAC activity, respectively.
Fiskus et al.(34) reported that panobinostat combined with
nilotinib induced a greater loss of cell viability and apoptosis
of IM-resistant CML cells, including cells expressing BCR-
ABL with the T315I mutation, than panobinostat or nilotinib
alone. In that study, it was not determined how panobinostat
enhanced the activity of nilotinib, which structurally cannot
contact the BCR-ABL protein with the T315I mutation. For
the present study, we therefore chose to study ponatinib, which
can structurally contact the BCR-ABL protein with the T315I
mutation. Okabe et al.(35) reported that the combination of
vorinostat and ponatinib had synergistic effects against CML
cells including cells expressing BCR-ABL with the T315I
mutation. In their study, co-treatment with vorinostat and
ponatinib was cytotoxic towards Ba/F3/T315I cells and
Fig. 4. Effect of panobinostat and/or ponatinib on
apoptosis of CML cell lines. The CML cell lines were
treated for 48 h with the indicated concentrations
of panobinostat or ponatinib, alone or in
combination. Apoptotic cell death was evaluated by
FACS analysis of annexin V positivity (a–d). (e) The
pro-apoptotic effect of treatment of Ba/F3/T315I
cells with 50 nM ponatinib alone, with a
combination of 30 nM ponatinib and 30 nM
panobinostat, or with 30 nM panobinostat alone
was also evaluated. N.S., not significant (P > 0.05).
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ponatinib-resistant Ba/F3 cells through reduction in the phos-
phorylation of CRKL, a signaling molecule downstream of
BCR-ABL, and through enhancement of caspase 3 and poly
(ADP-ribose) polymerase activity. Our present study showed
that the combination of panobinostat and ponatinib also dis-
played synergistic antiproliferative and cytotoxic effects
towards not only cells expressing BCR-ABL with the T315I
mutation but also towards cells with BCR-ABL gene amplifica-
tion (Figs 2–4d). Moreover, we showed that panobinostat and
the combination of panobinostat with ponatinib inhibited
HDAC activity (Fig. 6), induced histone H3 acetylation
(Fig. 7a), and augmented HSP70 expression (Fig. 7b). These
data suggest that the combination of panobinostat and pona-
tinib may hold promise for the treatment of IM-resistant cells.
The BCR-ABL protein activates several molecular mecha-
nisms to inhibit apoptosis.(33) Thus, BCR-ABL increases the
phosphorylation and the activity of STAT5, resulting in
increased expression of the anti-apoptotic BCL-XL protein.
BCR-ABL also induces activation of the phosphoinositide 3-
kinase pathway, resulting in activated AKT kinase that leads
to the phosphorylation and inactivation of downstream signal-
ing proteins such as Bcl-2-associated death promoter and cas-
pase 9 that regulate apoptosis. Moreover, BCR-ABL activates
Ras/Raf/ERK1/2 and nuclear factor-kB activities, which
together inhibit apoptosis through multiple mechanisms.(33,36)
In the present study, ponatinib inhibited both the autophos-
phorylation of BCR-ABL and phosphorylation of downstream
signaling molecules, resulting in the induction of apoptosis. It
Fig. 5. Effect of panobinostat and/or ponatinib on the expression of BCR-ABL, phospho-BCR-ABL, and downstream signaling molecules in CML
cell lines. All cell lines were treated for 24 h with panobinostat, ponatinib, or their combination at the indicated concentrations followed by
Western blotting of BCR-ABL expression (a). (b–e) (1) Western blotting of BCR-ABL, STAT5, AKT, and ERK1/2 proteins (top) or their phosphory-
lated (p-) forms (bottom). b-Actin was assayed as a loading control. Band intensity was determined using densitometry and is indicated below
each band. (b–e) (2) The combination of ponatinib with panobinostat at the indicated concentrations inhibited p-BCR-ABL expression more
strongly than the sum of each agent alone.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | July 2016 | vol. 107 | no. 7 | 1034
Original Article
Panobinostat and ponatnib against imatinib-resistant CML www.wileyonlinelibrary.com/journal/cas
has been reported that panobinostat also decreases the levels
of generic oncogenic targets, including not only BCR-ABL
but also Fms-related tyrosine kinase 3, c-Raf, and AKT
through attenuation of the chaperone function of
HSP90.(14,34,37) Heat shock protein 90 is a non-histone pro-
tein that is associated with HDAC6 and that functions as a
chaperone of the BCR-ABL protein, protecting it from degra-
dation. This protection of BCR-ABL supports activation of
the aforementioned downstream pathways, cell cycle prolifer-
ation, and apoptosis.(14) Accordingly, HSP90 has also been
previously suggested to be an important therapeutic target of
CML.(34,35)
In the present study, panobinostat reduced BCR-ABL and
AKT protein expression (Fig. 5b–e), and increased HSP70
levels (Fig. 7b). These data are suggestive of a decreased
chaperone function of HSP90 that would lead to the degrada-
tion of BCR-ABL in both wild-type and IM-resistant
cells.(14,33,34,38) Moreover, the induction of histone H3 acetyla-
tion by panobinostat (Fig. 7a) was consistent with a previous
report that panobinostat did not exert antiproliferative effects
without induction of acetylated histone H3.(14) Importantly it
was observed that the autophosphorylation of BCR-ABL fol-
lowing treatment with the combination of ponatinib and
panobinostat was lower than that following treatment with
either agent alone. These results suggested that inhibition of
the phosphorylation of BCR-ABL by ponatinib combined
with the degradation of BCR-ABL and AKT induced by
panobinostat would exert synergistic inhibitory effects on
BCR-ABL signaling.
In the HDAC assay, panobinostat alone or the combination
of panobinostat with ponatinib reduced HDAC activity
(Fig. 6). The reduction in HDAC activity tended to be greater
when the cells were treated with ponatinib together with
panobinostat compared to treatment with panobinostat alone
(P = 0.33 for K562 cells, P = 0.16 for K562/IM-R1 cells,
P = 0.16 for Ba/F3 cells, and P = 0.18 for Ba/F3/T315I cells;
panobinostat versus panobinostat plus ponatinib). Gonzalez-
Zu~niga et al.(39) reported that, in Alzheimer’s disease, c-abl
stabilized HDAC2, resulting in the repression of neuronal gene
expression. In that study, a transgenic mouse model of
Fig. 5. continued.
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Alzheimer’s disease was treated with IM, which resulted in
decreased HDAC2 levels, suggesting that the BCR-ABL pro-
tein was also involved in stabilizing HDAC activity. Therefore,
ponatinib might also be associated with the regulation of
HDAC through unknown epigenetic mechanisms.
Adverse clinical effects of ponatinib include serious vascular
occlusion events such as myocardial infarction or stroke.(40) In
the PACE trial, patients usually take ponatinib at a dose of
45 mg/day (as a starting dose).(17) It was reported that the
trough level of ponatinib reaches 40 nM when patients take
ponatinib at a dose of 30 mg/day.(41,42) In our study, even in
IM-resistant cells that display active BCR-ABL, including
BCR-ABL with the T315I mutation, combination therapy of
panobinostat and ponatinib at a dosage of 30 nM per agent
Fig. 6. Effect of panobinostat or panobinostat plus
ponatinib on histone deacetylase (HDAC) activity in
CML cell lines. All cell lines were treated for 12 h
with the indicated concentration of panobinostat or
panobinostat plus ponatinib. HDAC activity was then
determined using an HDAC assay kit. Activity is
indicated relative to that in the absence of treatment
(100%). K562, *P = 0.026, **P = 0.023; K562/IM-R1,
*P = 0.047, **P = 0.013; Ba/F3, *P = 0.014,
**P = 0.037; Ba/F3/T315I, *P = 0.025, **P = 0.041.
N.S., not significant (P > 0.05).
Fig. 7. (a) Effect of panobinostat and/or ponatinib
on the acetylation status of histone H3 and on the
expression level of heat shock protein (HSP)70 in
CML cell lines. All cell lines were treated for 24 h
with panobinostat, ponatinib, or their combination
at the indicated concentrations. Western blotting
was then carried out to evaluate the protein
expression levels of histone H3 and acetylated
histone H3. b-Actin was assayed as a loading
control. (b) Western blotting was also used to
evaluate the protein expression levels of HSP90 and
HSP70 in K562 cells at 24 and 18 h, respectively,
after treatment with 10 nM panobinostat,
ponatinib, or their combination.
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exerted synergistic cytotoxic effects (Fig. 4d). Flow cytometric
analysis of apoptosis indicated that the combination of these
two agents at a concentration of 30 nM each agent had similar
cytotoxic effects towards Ba/F3/T315I cells as 50 nM pona-
tinib alone (Fig. 4e). O’Hare et al.(19) reported that ponatinib
suppressed the emergence of any single mutation of BCR-ABL
at a concentration of 40 nM. Our study suggested that, when
panobinostat is combined with ponatinib, low concentrations
of these agents might be sufficient to exert strong cytotoxic
effects towards CML cells, including towards IM-resistant
cells. Therefore, combining a low concentration of ponatinib
with a low concentration of panobinostat might be a possible
solution to the problem of adverse effects of higher concentra-
tions of ponatinib.
In conclusion, this is the first report on the combination of
ponatinib and panobinostat. We have clearly shown that treat-
ment with a combination of panobinostat and ponatinib syner-
gistically overcame IM resistance that was mediated either
though BCR-ABL gene amplification or through BCR-ABL
T315I mutation. This synergistic effect might be attributable to
inhibition of ABL kinase activity combined with degradation
of the BCR-ABL protein. The combination of these two agents
might offer a new therapeutic strategy with excellent anti-
CML activity and reduced toxicity.
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